Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China--Clover launches AdimFlu-S (QIS) in mainland China, the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older --
Clover Provides Updates on Business and R&D Pipeline Development-- Clover’s leading respiratory vaccine franchise to be strengthened from commercial launch of quadrivalent influenza vaccine (AdimFlu-S [QIS]) in mainland China in H2-2023 --
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China-- Clover to leverage Kyuan Trade’s extensive sales and distribution network to complement in-house capabilities and maximize access to its quadrivalent seasonal influenza vaccine, AdimFlu-S (QIS), across China --
Clover Announces Corporate Updates and Full Year 2022 Financial Results-- Clover’s two premium respiratory vaccines approved in China (COVID-19 and seasonal influenza) are expected to drive meaningful and diversified revenues in 2023 with continued growth thereafter --
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China-- Clover to leverage its established and growing commercial infrastructure to exclusively distribute Adimmune’s AdimFlu-S (QIS), the only imported quadrivalent influenza vaccine approved in mainland China --
UPDATE -- Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in Q1 2023--
Clover Launches COVID-19 Booster Vaccine in the People’s Republic of China--As part of China’s second booster campaign, Clover’s premium, broadly protective protein-based vaccine is now available in Zhejiang province with additional provinces and municipalities to follow in Q1 2023--
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China --
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo --
Clover Provides Update on 2022 Corporate Milestones-- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 --
